Credit Suisse’s Juno Therapeutics, Inc. JUNO Stock Holding History

Credit Suisse’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-260,490	Closed	-$11.9M	–	4239
2017 Q4	$11.9M	Buy	260,490 +62,548	+32%	+$3.12M	0.01%	1156
2017 Q3	$8.88M	Sell	197,942 -12,109	-6%	-$413K	0.01%	1324
2017 Q2	$6.28M	Sell	210,051 -95,542	-31%	-$2.36M	0.01%	1484
2017 Q1	$6.78M	Buy	305,593 +112,787	+58%	+$2.42M	0.01%	1437
2016 Q4	$3.63M	Buy	192,806 +5,544	+3%	+$136K	﹤0.01%	1905
2016 Q3	$5.62M	Buy	187,262 +63,346	+51%	+$1.97M	0.01%	1573
2016 Q2	$4.76M	Sell	123,916 -14,196	-10%	-$589K	0.01%	1661
2016 Q1	$5.26M	Buy	138,112 +100,629	+268%	+$3.51M	0.01%	1492
2015 Q4	$1.65M	Buy	+37,483	New	+$1.86M	﹤0.01%	2424
2015 Q3	–	Sell	-56,151	Closed	-$3M	–	4622
2015 Q2	$3M	Buy	+56,151	New	+$2.98M	﹤0.01%	2216

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Credit Suisse's JUNO Position: Q1 2018 in Review

Credit Suisse sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 260,490 shares — an estimated $11.9M sold.

Credit Suisse first reported a position in JUNO in Q2 2015 and held it in 10 quarters. The position peaked at $11.9M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Credit Suisse reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Credit Suisse sold 260,490 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $11.9M.
Credit Suisse first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 10 quarters.
Credit Suisse's Juno Therapeutics, Inc. position peaked at $11.9M in Q4 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Credit Suisse's 13F filing for Q1 2018, filed 15 May 2018.